Suppr超能文献

韩国(KROG 16-05)Child-Pugh 分类 B 患者接受分次适形放疗的肝癌治疗结果。

Treatment Outcome after Fractionated Conformal Radiotherapy for Hepatocellular Carcinoma in Patients with Child-Pugh Classification B in Korea (KROG 16-05).

机构信息

Department of Radiation Oncology, Soonchunhyang University College of Medicine, Bucheon, Korea.

Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

出版信息

Cancer Res Treat. 2019 Oct;51(4):1589-1599. doi: 10.4143/crt.2018.687. Epub 2019 Apr 10.

Abstract

PURPOSE

There is limited data on radiotherapy (RT) for hepatocellular carcinoma (HCC) in patients with Child-Pugh classification B (CP-B). This study aimed to evaluate the treatment outcomes of fractionated conformal RT in HCC patients with CP-B.

MATERIALS AND METHODS

We retrospectively reviewed the data of HCC patients with CP-B treated with RT between 2009 and 2014 at 13 institutions in Korea. HCC was diagnosed by the Korea guideline of 2009, and modern RT techniques were applied. Fraction size was ≤ 5 Gy and the biologically effective dose (BED) ≥ 40 Gy10 (α/β = 10 Gy). A total of 184 patients were included in this study.

RESULTS

Initial CP score was seven in 62.0% of patients, eight in 31.0%, and nine in 7.0%. Portal vein tumor thrombosis was present in 66.3% of patients. The BED ranged from 40.4 to 89.6 Gy10 (median, 56.0 Gy10). After RT completion, 48.4% of patients underwent additional treatment. The median overall survival (OS) was 9.4 months. The local progression-free survival and OS rates at 1 year were 58.9% and 39.8%, respectively. In the multivariate analysis, non-classic radiation-induced liver disease (RILD) (p < 0.001) and additional treatment (p < 0.001) were the most significant prognostic factors of OS. Among 132 evaluable patients without progressive disease, 19.7% experienced non-classic RILD. Normal liver volume was the most predictive dosimetric parameter of non-classic RILD.

CONCLUSION

Fractionated conformal RT showed favorable OS with a moderate risk non-classic RILD. The individual radiotherapy for CP-B could be cautiously applied weighing the survival benefits and the RILD risks.

摘要

目的

对于 Child-Pugh 分类为 B(CP-B)的肝细胞癌(HCC)患者,放射治疗(RT)的数据有限。本研究旨在评估 CP-B 型 HCC 患者接受分割适形 RT 的治疗结果。

材料和方法

我们回顾性分析了 2009 年至 2014 年韩国 13 家机构接受 RT 治疗的 CP-B 型 HCC 患者的数据。HCC 按照 2009 年韩国指南诊断,采用现代 RT 技术。分割剂量≤5Gy,生物有效剂量(BED)≥40Gy10(α/β=10Gy)。本研究共纳入 184 例患者。

结果

初诊时 CP 评分 7 分占 62.0%,8 分占 31.0%,9 分占 7.0%。66.3%的患者存在门静脉癌栓。BED 范围为 40.4 至 89.6Gy10(中位数 56.0Gy10)。RT 完成后,48.4%的患者接受了额外治疗。中位总生存期(OS)为 9.4 个月。1 年局部无进展生存率和 OS 率分别为 58.9%和 39.8%。多因素分析显示,非经典放射性肝损伤(RILD)(p<0.001)和额外治疗(p<0.001)是 OS 的最重要预后因素。在 132 例无进展疾病的可评估患者中,19.7%发生非经典 RILD。正常肝体积是预测非经典 RILD 的最具预测性的剂量学参数。

结论

分割适形 RT 显示出良好的 OS 结果,同时具有中度非经典 RILD 风险。对于 CP-B 患者,可以谨慎地应用个体化放疗,权衡生存获益和 RILD 风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/202d/6790850/22d9f1f1bca5/crt-2018-687f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验